CO5580763A2 - Inhibidores de fosfolipasa a2 citosolica - Google Patents

Inhibidores de fosfolipasa a2 citosolica

Info

Publication number
CO5580763A2
CO5580763A2 CO04050432A CO04050432A CO5580763A2 CO 5580763 A2 CO5580763 A2 CO 5580763A2 CO 04050432 A CO04050432 A CO 04050432A CO 04050432 A CO04050432 A CO 04050432A CO 5580763 A2 CO5580763 A2 CO 5580763A2
Authority
CO
Colombia
Prior art keywords
alkyl
integral number
imidazole
pyridinyl
cycloalkyl
Prior art date
Application number
CO04050432A
Other languages
English (en)
Inventor
John Caedmon Mckew
Steve Yik-Kai Tam
James Donald Clark
Katherine Lin Lee
Lihren Chen
Paresh Thakker
Fuk-Wah Sum
Mark Leo Behnke
Baihua Hu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CO5580763A2 publication Critical patent/CO5580763A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1.- Un compuesto de la fórmula:En la cual:R es seleccionado de la fórmula - (CH2)n-A, -(CH2)n-S-A, o -(CH )n-O-A, donde A es seleccionado entre las mitades: dondeD es alquilo inferior con C1-C6, alcoxi inferior con C1-C6, cicloalquilo con C3-C6, CF3 o -(CH2)1-3 -CF3;B y C independientemente son seleccionados entre fenilo; piridinilo, pirimidilo, furanilo, tiofenilo o grupos de pirrolilo, cada uno opcionalmente sustituido con desde 1 hasta 3, preferiblemente 1 hasta 2, sustituyentes seleccionados independientemente entre H, halógeno, -CN, -CHO, -CF3, -OCF3, -OH, -alquilo con C1-C6, alcoxi con C1-C6, -NH2, -N(alquilo con C1-C6)2, -NH(alquilo con C1-C6), N-C(O)-(alquilo con C1-C6), -NO2, o por un anillo heterocíclico o heteroaromático con 5 o 6 elementos que contiene 1 o 2 heteroátomos seleccionados entre O, N, o S; o n es un número íntegro desde 0 hasta 3;n1 es un número íntegro desde 1 hasta 3; n2 es un número integro desde 0 hasta 4; n3 es un número integro desde 0 hasta 3; n4 es un número íntegro desde 0 hasta 2;X1 es seleccionado entre un enlace químico, -S-, -O-, -S(O)-, -S(O)2-, -NH-, -NHC(O)-, -C=C-,R1 es una mitad seleccionada entre grupos de alquilo con C1-C6, alquilo fluorinado con C1-C6, cicloalquilo con C3-C6, tetrahidropiranilo, camforilo, adamantilo, CN, -N(alquilo con C1-C6)2, fenilo, piridinilo, piriminidilo furilo, tienilo, naftilo, morfolinilo, tiazolilo, pirazolilo, piperidinilo, pirrolidinilo, imidazolilo, piperazinilo, tiazolidinilo, tiomorfolinilo, tetrazola, indol, benzoxazol, benzofuran, imidazolidina-2-tiona, 7,7,diemetil-biciclo[2.2.1]heptan-2-ona, ...
CO04050432A 2001-12-03 2004-05-31 Inhibidores de fosfolipasa a2 citosolica CO5580763A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33460501P 2001-12-03 2001-12-03
US33459101P 2001-12-03 2001-12-03
US33458801P 2001-12-03 2001-12-03
US41966402P 2002-10-18 2002-10-18

Publications (1)

Publication Number Publication Date
CO5580763A2 true CO5580763A2 (es) 2005-11-30

Family

ID=27502498

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04050432A CO5580763A2 (es) 2001-12-03 2004-05-31 Inhibidores de fosfolipasa a2 citosolica

Country Status (25)

Country Link
EP (1) EP1451154B1 (es)
JP (1) JP4657605B2 (es)
KR (1) KR100973665B1 (es)
CN (1) CN100503566C (es)
AR (1) AR037684A1 (es)
AT (1) ATE384045T1 (es)
AU (1) AU2002351182B2 (es)
BR (1) BR0214672A (es)
CA (1) CA2469138C (es)
CO (1) CO5580763A2 (es)
CY (1) CY1107383T1 (es)
DE (1) DE60224707T2 (es)
DK (2) DK1892239T3 (es)
EC (1) ECSP045131A (es)
ES (2) ES2401454T3 (es)
HK (2) HK1065799A1 (es)
HU (1) HUP0402577A3 (es)
IL (2) IL162052A0 (es)
IN (1) IN2005KO00312A (es)
NO (1) NO327256B1 (es)
NZ (1) NZ533269A (es)
PL (1) PL370445A1 (es)
PT (1) PT1451154E (es)
TW (1) TWI334778B (es)
WO (1) WO2003048122A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
TW200510305A (en) * 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
DK1685104T3 (da) 2003-11-17 2008-04-14 Wyeth Corp Fremgangsmåde til fremstilling af N-substituerede phthalomider
HN2004000536A (es) * 2003-12-16 2009-02-18 Wyeth Corp Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles
AR048239A1 (es) 2004-02-25 2006-04-12 Wyeth Corp Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo e intermediarios de sintesis de los mismos
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
AR053410A1 (es) * 2004-08-19 2007-05-09 Wyeth Corp Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos. compuestos intermediarios
PL1719507T3 (pl) 2005-04-13 2010-12-31 Cipher Pharmaceuticals Inc Agoniści receptora beta2-adrenergicznego do leczenia chorób tkanki łącznej skóry
GT200600228A (es) * 2005-05-27 2006-12-26 Inhibidores de la fosfolipasa a2 citosolica
SG163550A1 (en) * 2005-07-21 2010-08-30 Wyeth Corp Process for the synthesis of sulfonyl halides and sulfonamides from sulfonic acid salts
JP2009514893A (ja) 2005-11-03 2009-04-09 イリプサ， インコーポレイテッド 多価インドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用
FR2899471A1 (fr) * 2006-04-06 2007-10-12 Pasteur Institut Utilisation d'au moins un inhibiteur de la phospholipase a2 cytosolique comme medicament pour le traitement des maladies respiratoires
WO2007140317A2 (en) * 2006-05-26 2007-12-06 Wyeth Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
CL2007003144A1 (es) * 2006-10-31 2008-06-20 Wyeth Corp Composicion farmaceutica que comprende a) un sistema portador o excipiente, con un agente tensioactivo desde un 50-90% en peso y un promotor de biodisponibilidad desde un 10-30% en peso y b) un agente farmacologico activo derivado de un indol; proced
CN101573111A (zh) * 2006-10-31 2009-11-04 惠氏公司 磷脂酶抑制剂的制剂
MX2009010302A (es) 2007-03-29 2009-10-16 Asubio Pharma Co Ltd Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion.
US8334314B2 (en) 2008-04-28 2012-12-18 Asahi Kasei Pharma Corporation Phenylpropionic acid derivative and use thereof
AU2010306750B2 (en) * 2009-10-15 2014-11-13 Children's Medical Center Corporation Sepiapterin reductase inhibitors for the treatment of pain
EP2614144B1 (en) 2010-09-08 2015-07-22 Twincore Zentrum für Experimentelle und Klinische Infektionsforschung GmbH Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079374C (en) * 1991-09-30 2003-08-05 Merck Frosst Canada Incorporated (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5994398A (en) * 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
CA2322162A1 (en) * 1998-02-25 1999-09-02 Genetics Institute, Llc Inhibitors of phospholipase enzymes
HUP0100757A3 (en) * 1998-02-25 2001-11-28 Genetics Inst Llc Cambridge Indole derivatives as inhibitors of phospholipase enzymes and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
TW200301695A (en) 2003-07-16
CA2469138C (en) 2012-04-17
DE60224707T2 (de) 2009-02-26
IN2005KO00312A (es) 2015-08-14
EP1451154A2 (en) 2004-09-01
IL162052A0 (en) 2005-11-20
AU2002351182B2 (en) 2009-01-15
TWI334778B (en) 2010-12-21
KR20050044661A (ko) 2005-05-12
CN100503566C (zh) 2009-06-24
ES2401454T3 (es) 2013-04-19
EP1451154B1 (en) 2008-01-16
NO327256B1 (no) 2009-05-25
CN1617855A (zh) 2005-05-18
HK1113798A1 (en) 2008-10-17
JP2005515997A (ja) 2005-06-02
DK1892239T3 (da) 2013-03-25
DE60224707D1 (de) 2008-03-06
DK1451154T3 (da) 2008-05-19
ATE384045T1 (de) 2008-02-15
KR100973665B1 (ko) 2010-08-04
NO20042679L (no) 2004-06-25
PT1451154E (pt) 2008-04-21
HUP0402577A2 (hu) 2005-03-29
HK1065799A1 (en) 2005-03-04
WO2003048122A3 (en) 2003-09-18
WO2003048122A2 (en) 2003-06-12
CY1107383T1 (el) 2012-12-19
CA2469138A1 (en) 2003-06-12
AU2002351182A1 (en) 2003-06-17
ECSP045131A (es) 2004-07-23
PL370445A1 (en) 2005-05-30
IL162052A (en) 2013-04-30
BR0214672A (pt) 2004-10-19
AR037684A1 (es) 2004-12-01
JP4657605B2 (ja) 2011-03-23
HUP0402577A3 (en) 2011-05-30
ES2300490T3 (es) 2008-06-16
NZ533269A (en) 2006-03-31

Similar Documents

Publication Publication Date Title
CO5580763A2 (es) Inhibidores de fosfolipasa a2 citosolica
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR112338A2 (es) Arilciclohexiléteres de dihidro-tetraazabenzoazuleno
CO5570698A2 (es) Nuevos compuestos de amida con accion antagonista de mch, y medicamentos que contienen estos compuestos
CY1112914T1 (el) Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
CO5700742A2 (es) Moduladores del receptor de quimioquina ccr5
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
MY140012A (en) Heterocylic substituted phenyl methanones
ES2546851T3 (es) Inhibidores de fosfatidilinositol 3-cinasa
CO5570676A2 (es) Nuevos compuestos de alquilo con efecto antagonico de la hcm y medicamentos que contienen estos compuestos
AR068056A1 (es) Derivados de n, n'-2, 4 - dianilinopirimidinas, su preparacion, su uso como medicamentos, composiciones farmaceuticas y especialmente como inhibidores de ikk.
AR049443A1 (es) Derivados de pirrolpiridinas
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
HUP0400326A2 (hu) Orexin receptor antagonistákként alkalmazható ciklikus N-(aril-karbonil)-amin-származékok és ezeket tartalmazó gyógyszerkészítmények
ES2393824T3 (es) Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucoquinasa para el tratamiento de diabetes mellitus
AR044629A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
AR055360A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
PE20120655A1 (es) Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map)
AU2001272476A1 (en) Piperidines for use as orexin receptor antagonists
AR050917A1 (es) Compuestos basados en 2-amido-tiazol que presentan actividad inhibidora de enzimas que utilizan atp, y composiciones y usos de los mismos
AR025386A1 (es) Moduladores de los receptores activados del proliferador de peroxisomas
AR063240A1 (es) Derivados de n-aril pirazol,composiciones farmaceuticas que los contienen y usos para el tratamiento de la diabetes tipo2,y enfermedades relacionadas.

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed